Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 20/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 0.80 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | HTR1D | P28221 | 1/20 | 0.58 |
| ▸ | HTR1B | P28222 | 1/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1161850 | 0.85 | MRGPRX1 (1.00) | MRGPRX1HTR2AHTR2BHTR2CDRD2 | |
| SCHEMBL1162417 | 0.74 | MRGPRX1 (1.00) | MRGPRX1HTR2AHTR2BHTR2CDRD2 | |
| SCHEMBL27873385 | 0.61 | MKNK1 (0.70) | — | |
| SCHEMBL21590413 | 0.61 | HTR2A (0.44) | MRGPRX1HTR2AHTR2BHTR2C | |
| SCHEMBL30694867 | 0.61 | HTR2A (0.44) | MRGPRX1HTR2AHTR2BHTR2C | |
| SCHEMBL24670708 | 0.61 | MEN1 (0.55) | MRGPRX1HTR2AHTR2BHTR2C | |
| SCHEMBL18658593 | 0.61 | CHRM3 (0.56) | MRGPRX1HTR2AHTR2BHTR2CDRD2 | |
| SCHEMBL7445054 | 0.61 | MCHR1 (0.49) | MRGPRX1HTR2AHTR2BHTR2C | |
| Hydrochloric Acid SCHEMBL7437697 | 0.60 | MCHR1 (0.48) | MRGPRX1HTR2AHTR2BHTR2C | |
| SCHEMBL12875869 | 0.60 | MKNK1 (0.68) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462435-A2 | IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN | California Institute of Technology (US) | 2012-06-13 | — | — | EP | claimed |
| US-20110150769-A1 | IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN | THE JOHN HOPKINS UNIVERSITY | 2011-06-23 | — | — | US | claimed |
| WO-2011017564-A2 | IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-02-10 | — | — | WO | claimed |
| EP-2462435-A2 | IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN | California Institute of Technology (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20110150769-A1 | IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN | THE JOHN HOPKINS UNIVERSITY | 2011-06-23 | — | — | US | disclosed |
| WO-2011017564-A2 | IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150769-A1 | IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN | MRGPRX1, MRGPRX2, OPRL1 | MRGPRX1 1/4885HTR2A 471/4885HTR2B 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.